A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

被引：0

作者：

Ye, Ding-Wei

Gu, Weijie

Han, Weiqing

Luo, Hong

Zhou, Fangjian

He, Dalin

Ma, Lulin

Guo, Hongqian

Liang, Chaozhao

Chong, Tie

Jiang, Jun

Chen, Zhiwen

Wang, Yong

Zou, Qing

Tian, Ye

Xiao, Jun

Huang, Jian

Yang, Xinfeng

Li, Junliang

Jin, Chunlei

机构：

[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[2] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Ctr, Changsha, Peoples R China

[3] Chongqing Univ, Canc Hosp, Chongqing Canc Hosp, Chongqing, Peoples R China

[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China

[5] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[6] Peking Univ Third Hosp, Beijing, Peoples R China

[7] Nanjing Drum Tower Hosp, Nanjing, Peoples R China

[8] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China

[9] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China

[10] Army Med Univ, Daping Hosp, Chongqing, Peoples R China

[11] Army Med Univ, Southwest Hosp, Chongqing, Peoples R China

[12] Tianjin Med Univ, Hosp 2, Tianjin, Peoples R China

[13] Jiangsu Canc Hosp, Nanjing, Peoples R China

[14] Capital Med Univ, Beijing Friendly Hosp, Beijing, Peoples R China

[15] USTC, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China

[16] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China

[17] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China

[18] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5003

引用

页数：1

共 50 条

[41] Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups
Hong, Jun Hyuk
Stenzl, Arnulf
Szmulewitz, Russell Z.
Petrylak, Daniel
Holzbeierlein, Jeffrey
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Y.
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Baron, Benoit
Haas, Gabriel P.
Morlock, Robert
Ramaswamy, Krishnan
Armstrong, Andrew J.
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 102 - 103
[42] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Stenzl, A.
Szmulewitz, R. Z.
Petrylak, D. P.
Holzbeierlein, J.
Villers, A.
Azad, A. A.
Alcaraz, A.
Alekseev, B. Y.
Iguchi, T.
Shore, N. D.
Rosbrook, B.
Baron, B.
Haas, G. P.
Morlock, R.
Ramaswamy, K.
Armstrong, A. J.
ANNALS OF ONCOLOGY, 2019, 30 : 332 - +
[43] Efficacy and safety of rezvilutamide (Rez) plus androgen- deprivation therapy (ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) aged ≤64, 65-74, and ≥75 years: Post-hoc analysis of randomized phase III CHART trial
Ye, D.
Bian, X.
Jiang, S.
Luo, H.
Zhou, F.
He, D.
Ma, L.
Guo, H.
Liang, C.
Chong, T.
Jiang, J.
Chen, Z.
Wang, Y.
Zou, Q.
Tian, Y.
Xiao, J.
Huang, J.
Yang, X.
Lian, J.
Wang, W.
ANNALS OF ONCOLOGY, 2024, 35 : S1531 - S1532
[44] Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
Zhuifeng Guo
Xuwei Lu
Fan Yang
Liang Qin
Ning Yang
Jiawen Wu
Hang Wang
European Journal of Medical Research, 27
[45] Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
Guo, Zhuifeng
Lu, Xuwei
Yang, Fan
Qin, Liang
Yang, Ning
Wu, Jiawen
Wang, Hang
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
[46] Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer A Randomized Clinical Trial
Vaishampayan, Ulka N.
Heilbrun, Lance K.
Monk, Paul, III
Tejwani, Sheela
Sonpavde, Guru
Hwang, Clara
Smith, Daryn
Jasti, Pallavi
Dobson, Kimberlee
Dickow, Brenda
Heath, Elisabeth I.
Semaan, Louie
Cher, Michael L.
Fontana, Joseph A.
Chinni, Sreenivasa
JAMA NETWORK OPEN, 2021, 4 (01) : E2034633
[47] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
Tan, Pui San
Aguiar Jr, Pedro
Haaland, Benjamin
Lopes, Gilberto
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (04) : 516 - 523
[48] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
Pui San Tan
Pedro Aguiar
Benjamin Haaland
Gilberto Lopes
Prostate Cancer and Prostatic Diseases, 2018, 21 : 516 - 523
[49] Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS
Tombal, B.
Smith, M. R.
Hussain, M.
Saad, F.
Fizazi, K.
Sternberg, C. N.
Crawford, E. D.
Kapur, S.
Zhang, W.
Ploeger, B.
Li, R.
Kuss, I.
Zieschang, C.
Wittemer-Rump, S.
Rezazadeh, Kalebasty A.
EUROPEAN UROLOGY, 2023, 83
[50] Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS
Saad, F.
Hussain, M.
Tombal, B.
Fizazi, K.
Sternberg, C. N.
Crawford, E. D.
Boegemann, M.
Tutrone, R.
Littleton, N.
Srinivasan, S.
Verholen, F.
Kuss, I.
Smith, M. R.
ANNALS OF ONCOLOGY, 2023, 34 : S964 - S964

← 1 2 3 4 5 →